The Worldwide Implantable Defibrillators Industry is Expected to Reach $5.6 Billion by 2030 - ResearchAndMarkets.com

The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, May 4, 2022
Information
Tags: 
Medical Devices, Health, Atrial fibrillation, Arrhythmia, Insurance, MRI, Infarction, Ventricular tachycardia, Ventricular fibrillation, Implantable cardioverter-defibrillator, Abdomen, ICD, Patient, Electrode, Incidence, ICDS, History, Skin, Arrest, Magnetic resonance imaging, Palpitations, CAGR, SCA, Boston Scientific, Technology, Heart, Growth, Ventricular septal defect, Heart rate, Medical device
Summary
Key Points: 
  • The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global implantable defibrillators market was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030.
  • Implantable defibrillators are battery-powered small devices placed underneath the chest or abdomen to keep track of a patient's heart rate.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market


The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The global implantable defibrillators market was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030.

Implantable cardioverter defibrillators (ICDs) are devices used to treat patients with heart arrhythmias that occur in the heart's lower chambers or ventricles, which can be life threatening.

ICDs are typically implanted in patients who have a weakened heart, owing to a history of heart blockages and/or heart attacks or in those with heart muscle tissue that are enlarged or thickened. Occasionally, ICDs are implanted in patients who have an inherited heart defect that makes their heart beat abnormally.

Implantable cardioverter defibrillator (ICD) is an equipment or device implanted inside the human body to perform cardioversion, correct pacing, and defibrillation of the heart. The product is generally used in treating sudden cardiac arrest owing to ventricular fibrillation, cardiac arrhythmias, and pulseless ventricular tachycardia.

Implantable defibrillators are battery-powered small devices placed underneath the chest or abdomen to keep track of a patient's heart rate. Increase in palpitation is diagnosed by the device and the normal heart rhythm is restored. These devices play a vital role in preventing sudden cardiac arrest in patients who suffer from sustained ventricular tachycardia or atrial fibrillation. Therefore, ICDs constantly monitor the heart rhythm through electrodes and deliver treatments when an abnormal heart rhythm is detected. The treatments through ICDs include pacing, cardioversion, and defibrillation to restore a normal heart rhythm.

The growth of the implantable defibrillators market is attributed to advancements in technology such as introduction of quadripolar lead devices to improve device programming, extend battery life, and development of magnetic resonance imaging (MRI)-safe ICDs. In addition, a rise in the incidence of atrial fibrillation and the high risk of a sudden cardiac arrest (SCA) fuel the demand for implantable defibrillator devices.

Furthermore, introduction of subcutaneous ICD technology in 2012 has revolutionized the treatment technology for cardiac rhythm management through these devices. Boston Scientific's S-ICDs were granted the market clearance in 2012, which was the first commercially available S-ICDs system worldwide. S-ICDs are widely adopted, as they are implanted below the skin without the leads to be placed inside the heart. This fueled the demand for S-ICDs globally, thus driving the growth of the market. However, the presence of alternative treatment and limited insurance coverage are projected to hamper the market growth.

Key Benefits

  • The report provides in-depth analysis of the global Implantable Defibrillators market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global Implantable Defibrillators market growth

Key Market Segments

By Product Type

  • Transvenous Implantable Cardioverter-Defibrillator (T-ICDs)
  • Subcutaneous Implantable Cardioverter Defibrillators (S-ICDS)
  • Cardiac Resynchronization Therapy Defibrillator (CRT-D)

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Players

  • Abbott
  • Biotronik SE & Co KG
  • Boston Scientific Corporation
  • Fukuda Denshi Co Ltd
  • Imricor Medical Systems
  • Koninklijke Philips NV
  • Livanova Plc Company
  • Medtronic Plc
  • Microport Scientific Corporation
  • Nohen Kohden Corporation

For more information about this report visit https://www.researchandmarkets.com/r/n36jt1

Copyright: 
Copyright Business Wire 2022